Member Info for stephen11

Lorna was grinning like the proverbial Cheshire cat in the video - and rightly so.

Super pleased for everyone.

Fair points Manxiety - time and results will be the judge.

Anyways, made some ££££ on HE1 today and have left some shares on a free run - always good to keep your options open 😀

GLA.

Stephen11.

Visit Timor is a Boil man - very knowledgeable poster.

05-Feb-24 09:36:41 2.45 1,000,000 Buy* 2.35 2.45 24.50k O

Hold tight everyone.

This rocket is about to go into orbit.

GLA.

Stephen11.

2.40 to buy on Hargreaves Lansdown Js15

Happy as Larry

It will be like an auction at 8 - whats my best option Fill or Kill or just take my chances at 8am?

Ps...pleased for Neil777 and the other faithfuls

Yea, JC definitely delivered the presentation with much more meat on the bones and was much more candid.

I respectfully disagree with Manxiety post about James Cheek and for the record he was a Director whilst working at Cepheid which had revenue of $4.3 Billion in 2022. I think he's the real deal.

James has previously worked for three of the worlds leading diagnostic companies. All the companies below have large American divisions - take your pick. That is:

Cepheid - Revenue for 2022 - $4.3 Billion

Beckman Coulter - Revenue for 2022 - $4.7 Billion

Roache Diagnostics Division - Revenue for 2022 - $17.7 Billion

I was extremely impressed with the new CEO, his strategies for commercialisation, and his vision for the company. Here's why:

- James brings a significant level of commercial and diagnostic experience gleaned from 20 years with Roache, Beckman Coulter, and Cepheid

- He has previously worked at board level in BIDVA where he gained specialist knowledge in NHS supply chain management and procurement procedures - experience which will prove invaluable to GDR

- The company intends to focus solely on pharmacogenetics i.e., specifically in the prevention of the prescription of drugs that produce Adverse Drug Reactions (ADRs) because the infectious diseases market is over saturated at present

- ADRs cost the NHS £2.2B in extra hospital days per year. Overall, pharmacogenetics testing could effect 30% of these cases, which in terms of health economics could save the NHS £660m per year

GLA.

Stephen11.

Informative info sharing from BigAl, Eureka, harrizma, and Occams as always - cheers guys.

The way I see it here is that it is just a waiting game for multiple good news RNSs in Feb and March.

We’ll get are Boil or HE1 day or two then a steady rise with commercial traction.

Buy more chips, hold your position and sit tight.

I took some more today aswell.

GLA.

Stephen11.

Well said that man harrizma . I like your style. I’ve been adding a cheeky 100, 000 each month at below 10p - will do the same tomorrow - all to play for 😊

I've just added 100, 000 shares in the last 2 days - not a large amount i know, but couldn't resist as they are as cheap as chips at these levels.

GLA.

Stephen11.

Very droll XYZ although I don’t think your ready for Britains Got Talent just yet!

Don't say you weren't warned about this - when she starts to move she really moves.

- May 5th 2020: GDRs SP was £2.19 (on the rumour of the COVID test - the government opted for inferior Chinese tests, but that's another story)

- Feb 12th May 2021: GDRs SP was £1.48 (on the back of the Beckman Coulter deal and FDA application for the COVID test, although unfortunately the Americans preferred their own tests).

The difference now is we have world firsts, in the AHIL and Stroke tests operating in a much less saturated market place.

The future is bright.

Stephen11.

Well done with HE1 Pollack 👍. That sort of rise doesn’t happen every day.

It’s all about timing and GDRs time WILL come.

What a classic 😊

*****Funding*****

- Funding: Q1 2024 - funding will be specifically for FDA of the MTRNR1 - RF drawdowns, sales, and tax credits will cover the monthly cash burn!

- I must remind everyone that Q1 runs to the 31st March 2024, so funding for FDA doesn't necessarily need to be imminent. Additionally, other funding options are available for FDA, such as a JV or some form of American partner deal, as JC eluded to

GLA.

Stephen11.

Regarding funding, the presentation states this will be needed in Q1, specifically for FDA submission. RF will be used to cover monthly cash burn before natural sales and commercial traction occur.

Q1 could mean January, February, or March 2024.

I’ll post more granular detail on this later.

GLA.

Stephen11.

Good info sharing John - thanks 👍